CHOLESTEROL AGENT Rx-TO-OTC SWITCHES WILL INCREASE PATIENT EDUCATION,BRISTOL DECLARES IN QUESTRAN PRESENTATION BEFORE FDA ADVISORY COMMITTEE
Executive Summary
An OTC switch of Bristol-Myers Squibb's cholesterol-lowering agent Questran would facilitate patient education about cholesterol management, the company asserted in advocating the switch before FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees Sept. 27.